183 related articles for article (PubMed ID: 38743443)
1. Combination of PEGylation and Cationization on Phospholipid-Coated Cyclosporine Nanosuspensions for Enhanced Ocular Drug Delivery.
Ma X; Liu Y; Wang J; Liu H; Wei G; Lu W; Liu Y
ACS Appl Mater Interfaces; 2024 May; 16(21):27040-27054. PubMed ID: 38743443
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine A Nanosuspensions for Ophthalmic Delivery: A Comparative Study between Cationic Nanoparticles and Drug-Core Mucus Penetrating Nanoparticles.
Yan R; Xu L; Wang Q; Wu Z; Zhang H; Gan L
Mol Pharm; 2021 Dec; 18(12):4290-4298. PubMed ID: 34731571
[TBL] [Abstract][Full Text] [Related]
3. Silk Fibroin Formed Bioadhesive Ophthalmic Gel for Dry Eye Syndrome Treatment.
Hao T; Tang L; Xu Q; Wang W; Li Z; Shen Y; Xu B; Luo H; Li Q; Wang J; Zhang J
AAPS PharmSciTech; 2024 Apr; 25(5):92. PubMed ID: 38684590
[TBL] [Abstract][Full Text] [Related]
4. A Novel Eyes Topical Drug Delivery System: CsA-LNC for the Treatment of DED.
Zhang A; Sun R; Ran M; Deng Y; Ge Y; Zhu Y; Tao X; Shang L; Gou J; He H; Yin T; Wang Y; Zhang Y; Tang X
Pharm Res; 2020 Jul; 37(7):146. PubMed ID: 32666340
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model.
Bang SP; Yeon CY; Adhikari N; Neupane S; Kim H; Lee DC; Son MJ; Lee HG; Kim JY; Jun JH
PLoS One; 2019; 14(11):e0224805. PubMed ID: 31738791
[TBL] [Abstract][Full Text] [Related]
6. Developing an in situ nanosuspension: a novel approach towards the efficient administration of poorly soluble drugs at the anterior eye.
Luschmann C; Tessmar J; Schoeberl S; Strauss O; Framme C; Luschmann K; Goepferich A
Eur J Pharm Sci; 2013 Nov; 50(3-4):385-92. PubMed ID: 23880334
[TBL] [Abstract][Full Text] [Related]
7. A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops.
Napoli PE; Braghiroli M; Iovino C; Demarinis G; Fossarello M
Drug Des Devel Ther; 2019; 13():2001-2008. PubMed ID: 31354245
[No Abstract] [Full Text] [Related]
8. Cationized hyaluronic acid coated spanlastics for cyclosporine A ocular delivery: Prolonged ocular retention, enhanced corneal permeation and improved tear production.
Liu Y; Wang Y; Yang J; Zhang H; Gan L
Int J Pharm; 2019 Jun; 565():133-142. PubMed ID: 31075435
[TBL] [Abstract][Full Text] [Related]
9. Phenylboronic-Acid-Based Polymeric Micelles for Mucoadhesive Anterior Segment Ocular Drug Delivery.
Prosperi-Porta G; Kedzior S; Muirhead B; Sheardown H
Biomacromolecules; 2016 Apr; 17(4):1449-57. PubMed ID: 26963738
[TBL] [Abstract][Full Text] [Related]
10. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
[TBL] [Abstract][Full Text] [Related]
12. Dual-ROS-scavenging and dual-lingering nanozyme-based eye drops alleviate dry eye disease.
Zhang W; Zhao M; Chu D; Chen H; Cui B; Ning Q; Wang X; Li Z; Cao S; Li J
J Nanobiotechnology; 2024 May; 22(1):229. PubMed ID: 38720321
[TBL] [Abstract][Full Text] [Related]
13. Ocular delivery systems for poorly soluble drugs: an in-vivo evaluation.
Luschmann C; Herrmann W; Strauss O; Luschmann K; Goepferich A
Int J Pharm; 2013 Oct; 455(1-2):331-7. PubMed ID: 23867983
[TBL] [Abstract][Full Text] [Related]
14. Oil-free eye drops containing Cyclosporine A/cyclodextrin/PVA supramolecular complex as a treatment modality for dry eye disease.
Chaudhari P; Birangal S; Mavlankar N; Pal A; Mallela LS; Roy S; Kodoth AK; Ghate V; Nampoothiri M; Lewis SA
Carbohydr Polym; 2022 Dec; 297():120007. PubMed ID: 36184135
[TBL] [Abstract][Full Text] [Related]
15. Topical cyclosporine A therapy for dry eye syndrome.
de Paiva CS; Pflugfelder SC; Ng SM; Akpek EK
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD010051. PubMed ID: 31517988
[TBL] [Abstract][Full Text] [Related]
16. Phenylboronic acid-tethered chondroitin sulfate-based mucoadhesive nanostructured lipid carriers for the treatment of dry eye syndrome.
Tan G; Li J; Song Y; Yu Y; Liu D; Pan W
Acta Biomater; 2019 Nov; 99():350-362. PubMed ID: 31449929
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine Amicellar delivery system for dry eyes.
Kang H; Cha KH; Cho W; Park J; Park HJ; Sun BK; Hyun SM; Hwang SJ
Int J Nanomedicine; 2016; 11():2921-33. PubMed ID: 27382280
[TBL] [Abstract][Full Text] [Related]
18. Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye.
Daull P; Nagano T; Gros E; Feraille L; Barabino S; Garrigue JS
Curr Eye Res; 2021 Aug; 46(8):1096-1104. PubMed ID: 33588656
[TBL] [Abstract][Full Text] [Related]
19. Gelatin-epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief.
Huang HY; Wang MC; Chen ZY; Chiu WY; Chen KH; Lin IC; Yang WV; Wu CC; Tseng CL
Int J Nanomedicine; 2018; 13():7251-7273. PubMed ID: 30510416
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
Aksungur P; Demirbilek M; Denkbaş EB; Vandervoort J; Ludwig A; Unlü N
J Control Release; 2011 May; 151(3):286-94. PubMed ID: 21241752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
